RESUMO
This cross-sectional study evaluated the immune status of non-vaccinated healthy infants to determine if it is possible to replace both measles vaccine (at 9 months) and measles, mumps and rubella (MMR) vaccine (at 18 months) with a single dose of MMR at 12 months. Serum samples from 566 children in Alexandria, Egypt showed a significant decrease in the seropositive rate to the 3 viral diseases with increasing age, but a significant increase in the seropositive rate among infants who were ranked 1st or 2nd in their family, full-term or born to mothers with no history of hypertension during pregnancy. We recommend administration of the first dose of MMR vaccine between 9 and 12 months of age, and a booster dose of MMR vaccine at 4 years of age.
Assuntos
Vacina contra Sarampo , Vacina contra Sarampo-Caxumba-Rubéola , Avaliação das Necessidades/organização & administração , Vacinação/métodos , Fatores Etários , Análise de Variância , Pré-Escolar , Estudos Transversais , Egito/epidemiologia , Feminino , Diretrizes para o Planejamento em Saúde , Humanos , Esquemas de Imunização , Imunização Secundária/métodos , Lactente , Recém-Nascido , Masculino , Sarampo/epidemiologia , Sarampo/imunologia , Sarampo/prevenção & controle , Vacina contra Sarampo/administração & dosagem , Vacina contra Sarampo/imunologia , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Vacina contra Sarampo-Caxumba-Rubéola/imunologia , Caxumba/epidemiologia , Caxumba/imunologia , Caxumba/prevenção & controle , Rubéola (Sarampo Alemão)/epidemiologia , Rubéola (Sarampo Alemão)/imunologia , Rubéola (Sarampo Alemão)/prevenção & controle , Estudos SoroepidemiológicosRESUMO
This cross-sectional study evaluated the immune status of non-vaccinated healthy infants to determine if it is possible to replace both measles vaccine [at 9 months] and measles, mumps and rubella [MMR] vaccine [at 18 months] with a single dose of MMR at 12 months. Serum samples from 566 children in Alexandria, Egypt showed a significant decrease in the seropositive rate to the 3 viral diseases with increasing age, but a significant increase in the seropositive rate among infants who were ranked 1st or 2nd in their family, full-term or born to mothers with no history of hypertension during pregnancy. We recommend administration of the first dose of MMR vaccine between 9 and 12 months of age, and a booster dose of MMR vaccine at 4 years of age
Assuntos
Vacina contra Sarampo , Estudos Transversais , Vacina contra Sarampo-Caxumba-Rubéola , Idade GestacionalRESUMO
We assessed the long-term immunity to hepatitis B among 242 Egyptian children aged 6-12 years who had received a full vaccination course in infancy, and investigated the factors associated with immunity. Only 39.4% of the children had protective (> or = 10 lU/L) hepatitis B surface antibody levels (HBsAb). This proportion decreased with age but the decrease was not statistically significant. The mean level of HBsAb decreased significantly with increasing age (P = 0.026). A significant negative correlation was found between current age and HBsAb levels (r = -0.31, P = 0.041). Age and weight-for-age were found to be significant predictors of non-protective HBsAb levels.
Assuntos
Anticorpos Anti-Hepatite B/sangue , Vacinas contra Hepatite B/imunologia , Vacinação , Fatores Etários , Peso Corporal , Criança , Estudos Transversais , Egito , Feminino , Necessidades e Demandas de Serviços de Saúde , Antígenos de Superfície da Hepatite B/imunologia , Humanos , Imunidade Ativa , Esquemas de Imunização , Imunização Secundária , Modelos Logísticos , Masculino , Análise Multivariada , Programas Nacionais de Saúde , Fatores de Risco , Estudos Soroepidemiológicos , Fatores Socioeconômicos , Inquéritos e Questionários , Saúde da População Urbana/estatística & dados numéricos , Vacinação/métodosRESUMO
We assessed the long-term immunity to hepatitis B among 242 Egyptian children aged 6-12 years who had received a full vaccination course in infancy, and investigated the factors associated with immunity. Only 39.4% of the children had protective [>/= 10 IU/L] hepatitis B surface antibody levels [HBsAb]. This proportion decreased with age but the decrease was not statistically significant. The mean level of HBsAb decreased significantly with increasing age [P = 0.026]. A significant negative correlation was found between current age and HBsAb levels [r = -0.31, P = 0.041]. Age and weight-for-age were found to be significant predictors of non-protective HBsAb levels
